Trial · NCT07913113
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 5-Year Overall Survival | Up to 5 years after enrollment | Time from enrollment to death from any cause, assessed up to 5 years after enrollment. OS will be estimated by the Kaplan-Meier method and compared between groups using the log-rank test. |
| Secondary | Overall Survival Rate at 1 Year | 1 year after enrollment | Percentage of participants alive at 1 year after enrollment, estimated by the Kaplan-Meier method. |
| Secondary | Overall Survival Rate at 3 Years | 3 years after enrollment | Percentage of participants alive at 3 years after enrollment, estimated by the Kaplan-Meier method. |
| Secondary | Progression-Free Survival | Up to 5 years after enrollment | Time from enrollment to radiological progression (per RECIST 1.1) or death from any cause, whichever occurs first, assessed in the conventional medical therapy group. |
| Secondary | Post-transplant Disease-Free Survival | Up to 5 years after liver transplantation | Time from liver transplantation to first radiological recurrence or death from any cause, whichever occurs first, assessed in the liver transplantation group. |
| Secondary | Recurrence Pattern After Liver Transplantation | Up to 5 years after liver transplantation | Anatomic pattern of first recurrence, categorized as intrahepatic (graft) recurrence or extrahepatic recurrence. |
| Secondary | Treatment-Related Adverse Events | Up to 5 years after enrollment | Percentage of participants experiencing treatment-emergent adverse events, graded by severity according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, including post-transplant surgical complications, graft-related events, and systemic drug toxicities. |
| Secondary | Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Score | Baseline, 6 months, 1 year, and annually thereafter up to 5 years | The EORTC QLQ-C30 global health status/quality of life subscale score ranges from 0 to 100, with higher scores indicating better quality of life. |
| Secondary | Total Direct Medical Costs | Up to 5 years after enrollment | Total direct medical costs attributable to the treatment course, including surgery, hospitalization, systemic therapy, and management of adverse events, reported in Chinese Yuan (CNY). |
| Secondary | Exploratory Prognostic Value of Ki-67 Proliferation Index | Baseline | Ki-67 proliferation index (percentage of positively stained tumor cell nuclei) assessed by immunohistochemistry on tumor tissue; ranges from 0% to 100%, with higher values indicating higher proliferative activity. |
| Secondary | Exploratory Prognostic Value of Serum Chromogranin A | Baseline, every 3 months up to 5 years | Serum chromogranin A concentration measured by immunoassay, reported in ng/mL; higher values may indicate greater tumor burden. |
| Secondary | Exploratory Prognostic Value of NETest Multigene Blood-Based Biomarker Score | Baseline, every 6 months up to 5 years | NETest multigene assay score based on circulating neuroendocrine tumor transcripts, reported as a normalized score from 0 to 100, with higher scores indicating more active disease. |
| Secondary | Neuroendocrine Tumor-Specific Symptoms Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Neuroendocrine and Gastrointestinal Tumors (EORTC QLQ-GINET21) Score | Baseline, 6 months, 1 year, and annually thereafter up to 5 years | The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Neuroendocrine and Gastrointestinal Tumors (EORTC QLQ-GINET21) score ranges from a minimum of 0 to a maximum of 100, with higher scores indicating a greater burden of disease-specific symptoms, i.e., a worse outcome. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07913113/registered